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Tumors comprising the spectrum of hemangiopericytoma/ malignant solitary 
fibrous tumor (HPC/SFT) are thought to arise from fibroblasts and represent a small 
subset of soft tissue sarcomas. Surgery is typically the treatment of choice for 
localized disease, with reported 10-year overall survival rates of 54-89% after 
complete surgical resection. However, for the approximately 20% of HPC/SFT 
patients who eventually develop local recurrences and/or distant metastases, 
options for effective treatment are limited and are poorly defined. Alternative 
therapeutic options are therefore needed for improved palliation and disease 
control. We hypothesize that HPC/SFT are a spectrum of soft tissue tumors with 
unique clinical, pathological, and molecular makeup and clinical behavior.  
HPC/SFT respond to unique therapeutic agents that specifically target aberrations 
specific to these tumors.   
We retrospectively reviewed the characteristics and the clinical outcomes for 
all HPC/SFT patients whose tumor specimens have been reviewed at the MD 
Anderson Cancer Center from January 1993 to June 2007 by a MD Anderson 
pathologist and were treated at the institution with available electronic medical 
records. We identified 128 patients, 79 with primary localized disease and 49 with 
recurrent and/or metastatic disease. For the 23 patients with advanced HPC/SFT 
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who received adriamycin-based, gemcitabine based, or paclitaxel chemotherapy as 
first- or second-line therapy, the overall RECIST response rate was 0%.  Most 
patients achieved a brief duration of disease stabilization on chemotherapy, with 
median progression-free survival (PFS) period of 4.6 months.  For the 14 patients 
with advanced HPC/SFT who received temozolomide and bevacizumab systemic 
therapy, the overall RECIST response rate was 14%, with the overall Choi response 
rate of 79%.  The median PFS for the cohort was 9.7 months with a median 6-
month progression free rate of 78.6%. The most frequently observed toxic effect of 
temzolomide-bevacizumab therapy was myelosuppression. We have designed a 
phase II study to evaluate the safety and efficacy of temozolomide-bevaciumab in 
locally advanced, recurrent, and metastatic HPC/SFT in a prospective manner.  
Combination therapy with temozolomide and bevacizumab may be a 
potentially clinically beneficial regimen for advanced HPC/SFT patients. 
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Chapter 1 
INTRODUCTION 
 
Hemangiopericytoma and Solitary Fibrous Tumor.  Tumors comprising the 
spectrum of hemangiopericytoma/ solitary fibrous tumor (HPC/SFT) are rare entities 
that represent a small subset of soft tissue sarcomas.  Stout and Murray first 
described HPC in 1942 as a distinct vascular soft tissue tumor characterized by 
groups of endothelial-lined tubes and sprouts, featuring Zimmerman’s pericytes. (1)   
Essential features of the diagnosis of HPC include the presence of well-developed 
branching “staghorn” thick-walled vessels surrounded by connective tissue sheath, 
moderate-to-high cellularity, and monotonous appearance under light microscopy 
examination. (2)  Classically, HPC tumors express immunohistochemical (IHC) 
positivity for muscle-specific actin (HHF-35), smooth muscle actin (SMA), 
tropomyosin and CD34, and negativity for desmin and h-caldesmon. (2)  However, 
only 10-20% of HPC display this classic expression pattern, with the majority 
showing non-specific patterns. (2)  Solitary fibrous tumor (SFT) was first recognized 
as a unique neoplasm by Klemperer and Rabin in 1931. (Klemperer 1931) SFT 
demonstrate a wide variety of histological features under light microscopy: 
multinodular, partially sclerotic pattens; HPC-like patterns displaying many thin 
walled staghorn branching vessels; and hypocellular, fibrous areas alternating with 
a monotous, highly cellular “patternless pattern” are all seen. (3) 
Immunohistochemical reactivity for CD34, CD99, bcl-2, and vimentin in the setting 
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of negativity for desmin, cytokeratins, and S-100, is a key characteristic of SFT, but 
such patterns are variable across cases. (2)  
 
The Hemangiopericytoma/ Solitary Fibrous Tumor (HPC/SFT) Spectrum: An 
Evolving Concept.  Much confusion and debate exist regarding the exact cell of 
origin and a clear set of classification criteria for HPC and SFT.  Because of the 
large overlap of morphologic and clinical features between HPC and SFT, the two 
entities have been frequently misdiagnosed for each other. In the most recent WHO 
classification of soft tisse sarcomas, the concept of HPC as a vascular, pericyte-
derived tumor was abandoned in favor of a fibroblastic cell of origin, thus placing 
HPC more closely with SFT. (4)  Therefore, the current paradigm has begun to view 
HPC and SFT as a spectrum of a single entity, a viewpoint which will be adopted in 
this study. 
 
Natural history of HPC/SFT.  HPC/SFT primarily occur in adults between ages 20-
70, with an equal frequency between men and women. (5)  SFT was first identified 
in the pleura and has classically been described as a neoplasm involving the 
serosal surfaces, i.e. pleural, pericardial, or peritoneal. However, as more cases of 
extrapleural SFT were reported, and as the diagnoses of HPC and SFT became 
more aligned with each other, HPC/SFT has been described as a malignancy 
affecting virtually every body site. (5-7)  The most commonly affected sites include 
the lower extremities, abdomen/pelvic fossa, lung/pleura, and head and neck 
(especially the supratentorial meninges), with additional sites including breast, 
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greater omentum, peritoneum, liver, stomach, uterus, ovary and vagina also 
reported in literature. (5, 8-11)  
 HPC/SFT are often present for several years prior to diagnosis, and most 
patients present with symptoms related to local growth.  A slow-growing mass or 
pain associated with locoregional pressure by the tumor are the most common. (5) 
Other symptoms related to the specific tumor site include urinary retention, 
constipation, (retroperitoneum and pelvic fossa), cough, dyspnea (lung and pleura), 
vomiting, headache (meninges), unitlateral varicose veins or telangiectasia of 
overlying skin (extremities). (5, 8)  A small number of HPC/SFT patients exhibit 
Doege-Potter syndrome, hypoglycemia which is thought to be mediated by 
overexpression of insulin-like growth factors (IGFs) produced by the tumor. (12, 13) 
Resolution of hypoglycemia occurs after tumor resection. 
 
Clinical management of HPC/SFT.  For localized disease, complete surgical 
resection is often the treatment of choice.  Retrospective analyses of the outcomes 
of HPC/SFT patients who had undergone initial surgery show that favorable long-
term outcomes can be achieved after complete surgical resection, with estimated 5-
year overall survival rates of 79-100%. (10, 14, 15)  Patients with incomplete 
surgical resection of their primary disease, however, have worse long-term 
prognosis, with an estimated 10-yr overall survival of 50%.  
 Approximately 15-20% of primary HPC/SFT recur, either locally or distally, 
after initial surgical resection.  Factors that are associated with an increased risk of 
developing disease recurrence include larger tumor size ( >10 cm), non-extremities 
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primary tumor location, and the presence of “malignant” histology. (10, 14, 15) 
Histological features of “malignant” HPC/SFT tumors include a high number of 
mitotic figures ( ≥ 4/10 mitoses/HPF), cellular atypia, and the presence of necrosis 
and/or hemorrhage, and tumors lacking such features are classified as “benign”. (2) 
Malignant histology alone, however, does not always predict aggressive clinical 
behavior.  Likewise, the clinical behavior and the prognosis of “benign” tumors also 
cannot be reliably predicted. (2, 4) Given this lack of clear prognostic indicators, all 
HPC/SFT patients should undergo long-term follow-up, since late recurrences 
(more than 20 years) can occur. (5)  
 Management of recurrent HPC/SFT is challenging, since no clearly effective 
strategies are known.  Additional surgeries should be attempted for isolated local 
and/or distant lesions, but they are not always feasible nor successful. (9, 10) 
Palliative radiation therapy has some role in controlling symptomatic lesions. 
Stereotactic radiosurgery in recurrent, unresectable HPC/SFT of the central nervous 
system may also produce some degree of durable disease control. (16)  
 Limited published data regarding the effectiveness of systemic chemotherapy 
in HPC/SFT are available. Doxorubicin- and/or ifosfamide-based regimens have 
most often been used, as well as gemcitabine-docetaxel. (10, 17-19) Systemic 
chemotherapy seems to be ineffective in the management of advanced HPC/SFT. A 
recent single-institution retrospective analysis of 13 HPC/SFT patients treated with 
doxorubicin- or ifosfamide-based therapy showed that only 1 of 9 (11%) and 4 of 4 
(0%) patients, respectively, had response. (18)  The exact efficacy of standard of 
5 
 
care chemotherapy regimens in advanced HPC/SFT, however, is yet poorly 
defined. 
 
Potential role of antiangiogenic therapy in HPC/SFT. HPC/SFT are highly 
vascular tumor tumors, and agents that modulate or inhibit angiogenesis, therefore, 
are rational and attractive therapeutic possibilities in treatment of HPC/SFT.  Case 
reports of advanced HPC/SFT patients who were treated with IFN-α and/or 
thalidomide showed durable disease stabilization for 16-41 months. (20, 21)  
Recently, several inhibitors of the vascular endothelial growth factor (VEGF) 
pathway, the key mediator of angiogenesis, have been evaluated in soft tissue 
sarcoma in phase II trials.  A small number of HPC/SFT patients underwent 
treatment with sunitinib, sorafenib, or pazopanib -- vascular endothelial growth 
factor receptor (VEGFR) tyrosine kinase inhibitors – and a few patients 
demonstrated durable stable disease up to 22 months. (22-25)  These cases thus 
suggest that angiogenesis may play a major role in HPC/SFT tumorigenesis, and 
that targeting the VEGF-VEGFR pathway may produce clinically effective outcomes 
in HPC/SFT patients. 
 Temozolomide (TMZ) and bevacizumab (BEV) combination therapy is 
another regimen that offers therapeutic promise in HPC/SFT. TMZ is an oral 
cytotoxic alkylating agent whose active metabolite, monomethyltriazenoimidazole 
carboxamide is identical to that of dacarbazine, which has known antitumor activity 
against soft tissue sarcomas. (26, 27) BEV is a recombinant monoclonal antibody 
that targets VEGF. BEV has shown antitumor activity when combined with a 
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number of cytotoxic chemotherapeutic agents, such that its use in combination 
therapy has been approved for the treatment of metastatic colorectal, non-small cell 
lung, and HER2-negative breast cancers. (28-30) 
TMZ was initially approved for the treatment of recurrent high grade glioma at 
a dose of 150-200 mg/m2/day for 5 consecutive days in a 28-day cycle. (31, 32) 
Subsequently, alternative dosing regimens using higher cumulative concentrations 
were developed in advanced high grade glioma patients.  In one phase I study, 32 
subjects with solid malignancies were sequentially enrolled into the following dose 
cohorts: 50, 75, 100, 125, 150, and 175 mg/m2/day using a 7-days-on/7-days-off 
(“dose-dense”) schedule. (33) TMZ was administered PO, in the morning of days 1 
through 7 and days 15 through 21 per cycle. Treatment cycles were repeated every 
28 days.  TMZ was rapidly absorbed and eliminated following PO administration. 
The MTD dose of 150 mg/m2 determined for this study.  In a phase II study of TMZ 
at 150 mg/m2/d on days 1 through 7 and 15 through 21 every 28 days, 90 patients 
with recurrent gliomas were treated, achieving a 6-month PFS rate clinically 
meaningful and statistically superior than that achieved with convenetional 5-day 
TMZ dosing. (34) Major toxicities seen in this study, while more frequent than those 
of conventional TMZ dosing regimens, were acceptable: CTCAE grade 4 
hematotoxicity was only observed in 2.6% of patients, with grade 4 lymphopenia in 
12% of patients.  No opportunistic infections were seen. Thrombocytopenia was the 
next most frequently observed toxicity, with CTCAE grade 3 and 4 toxcities 
observed in 8.5% and 1.9%, respectively. 
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 In clinical practice, BEV is used in combination with cytotoxic chemotherapy 
in doses ranging from 5 mg/kg to 15 mg/kg. The maximum tolerated dose of BEV 
has not been determined. However, recruitment into the 20 mg/kg every-2-weeks 
dose group of a BEV monotherapy study in patients with metastatic breast cancer 
was prematurely suspended due to severe headache associated with nausea and 
vomiting occurring in 4 of 16 patients (25%) in this dose group. This is the highest 
dose tested in humans.  The ideal biologically effective dose of BEV is unknown. 
The most serious adverse events associated with BEV treatment are 
gastrointestinal perforations, fistulae, hemorrhage (including tumor-associated, 
mucocutaneous and intracranial), arterial and venous thromboembolic events and 
wound healing complications. Increased rates of severe neutropenia, febrile 
neutropenia, or infection with severe neutropenia (including some fatalities) have 
been observed in patients treated with some myelotoxic chemotherapy regimens 
plus BEV in comparison to chemotherapy alone. Hypertension and proteinuria are 
also associated with BEV therapy, and there is some evidence from the dose-
finding Phase II trials that they are likely to be dose-dependent. Information from 
marketing experience identified hypertensive encephalopathy and reversible 
posterior leukoencephalopathy syndrome as rare events associated with BEV 
treatment.  (Avastin IB) 
The antitumor activity of TMZ combined with BEV is currently being studied 
in a number of different dosing schedules in several phase II and III trials in 
glioblastoma and malignant melanoma patients. (35)  Two recently published Phase 
II studies explored the safety and efficacy of TMZ in a conventional 5-day dosing 
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and in a lose-dose, metronomic dosing (50 mg/m2/day for 21 days in a 28-day 
cycle) combinbed with BEV 10 mg/kg with expected side effect profiles. (36, 37) 
 In May 2005, a patient with a recurrent meningeal HPC that was refractory to 
multiple surgical resections, radiotherapy, and chemotherapy was empirically 
treated with TMZ and BEV at our institution.  He subsequently achieved a 
radiologically evident reduction in tumor size as well as palliation of tumor-related 
symptoms.  This anecdotal evidence led us to treat additional patients who had 
locally advanced, recurrent, or metastatic HPC/SFT not amenable to surgery with 
TMZ-BEV regimen.  We hypothesized that HPC/SFT patients treated with TMZ-BEV 
would achieve at least similar degree of disease control, if not superior, as standard 
of care chemotherapy regimens. 
 
Hypotheses and Specific Aims. I hypothesized that HPC/SFT are a spectrum of 
soft tissue tumors with unique clinical, pathological, and molecular makeup and 
clinical behavior.  HPC/SFT respond to unique therapeutic agents that specifically 
target aberrations specific to these tumors.  To test my hypothesis I designed the 
following specific aims: 
1. To estimate the overall response rate (ORR) and progression-free survival 
(PFS) of advanced HPC/SFT patients who were treated systemic 
chemotherapy, especially those with doxorubicin-based, gemcitabine-based 
or paclitaxel-based chemotherapy. 
9 
 
2. To describe the activity of TMZ-BEV therapy in advanced HPC/SFT and 
identify potential clinicopathological factor(s) that correlate with response to 
therapy and outcome. 
3. To design a prospective phase II trial to determine the efficacy of TMZ-BEV 
regimen in locally advanced, recurrent, and metastatic HPC/SFT. 
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Chapter 2 
METHODS 
 
AIM 1: To estimate the overall response rate (ORR) and progression-free survival 
(PFS) of advanced HPC/SFT patients who were treated systemic chemotherapy, 
especially those with doxorubicin-based, gemcitabine-based or paclitaxel-based 
chemotherapy. 
 
Patient selection: 
Patient identification. The study was approved by the University of Texas M.D. 
Anderson Cancer Center institutional review board, and a waiver of consent was 
granted for the proposed patient record review.  All patients were initially identified 
from the soft tissue tumor pathology database at the M. D. Anderson Cancer 
Center. For all patients whose tumor specimens have been reviewed at the M. D. 
Anderson Cancer Center from January 1993 to June 2007 by a M. D. Anderson 
pathologist, the pathology reports containing the terms “hemangiopericytoma” or 
“solitary fibrous tumor” within the body of the text were identified.  The start time 
period was chosen to reflect the time period at which the patient records were 
available electronically.  The pathology reports were then reviewed by me to identify 
those patients whose pathologic diagnosis met the following categories: 1) HPC, 2) 
SFT, 3) HPC/SFT, 4) unclassified spindle cell neoplasm/tumor, mesenchymal cell 
tumor/neoplasm, or fibrosarcoma with additional comment by the pathologist 
subsequently identifying the tumor as HPC and/or SFT. Patients whose pathology 
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reports included HPC and/or SFT in the differential diagnosis but were ultimately 
determined to have another diagnosis were excluded. 
 The clinical records of the selected patients were then reviewed using the 
institutional electronic medical records database (ClinicStation).  All clinical 
encounters available in the database, as well as all available outside records which 
had been scanned into the system, were reviewed.  Patients who only had 
pathology reports in the system without clinical notes were excluded.  Patients who 
had pathology reports and were seen only at their initial visit without subsequent 
follow up visits at M. D. Anderson were also excluded. Pediatric patients, defined as 
age at diagnosis < 18, were also excluded. 
 
Clinicopathological Variables: 
 Patient demographic characteristics consisting of age at diagnosis, sex, race, 
and vital status as of April 1, 2010 were collected.  Primary tumor characteristics 
consisting of histologic diagnosis (HPC, SFT), site, size, histologic classification 
(benign, malignant, or unknown), and the presence of metastases, if any, were 
collected.  Site of primary tumor were categorized as central nervous system (CNS), 
head & neck, lung/pleura, abdomen/pelvis, extremities, or other. Tumor site and 
size were determined using pathology reports, operative reports, and/or radiologic 
examinations.  Available pathology reports were examined for the presence of a 
high number of mitotic figures (≥ 4/10 mitoses/HPF), cellular atypia, and the 
presence of necrosis and/or hemorrhage in the tumor.  Tumors containing one or 
more of these features were classified as malignant, and tumors lacking these 
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features were classified as benign.  Tumors whose pathology report did not 
describe these histologic features were classified as unknown.  
 For patients who were initially evaluated at the MD Anderson Cancer Center 
with primary localized disease, the dates and the resection status of the primary 
tumor were recorded; dates of surgery, gross total resection status and/or 
microscopic margin involvement were gathered from operative reports, clinical 
reports, and/or pathology reports.  Neo/ adjuvant radiation treatment status and 
neo/ adjuvant chemotherapy status was recorded.  Variables related to clinical 
outcome that were collected included the development of local recurrence and/or 
distant metastases, sites of recurrence, time to disease recurrence from initial 
diagnosis and overall survival.  
 For patients who were initially evaluated at the MD Anderson Cancer Center 
with locally recurrent disease or metastatic disease, treatment information regarding 
the surgical resection, neo/ adjuvant radiation, and neo/ adjuvant chemotherapy 
was gathered in the same fashion as the treatment of the primary tumor.  Time to 
disease progression from their initial treatment at MD Anderson Cancer Center and 
overall disease-specific survival were also calculated. 
 For patients with unresectable disease who received systemic 
chemotherapy, the chemotherapy regimen used, the number of cycles, the best 
response reached (for patients with measurable disease only), date of disease 
progression, and reasons for discontinuing therapy were collected. For patients 
whose radiologic scans were available, information regarding the best response and 
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disease progression was collected from direct measurement of the radiology report, 
if scans were available for measurements; radiology reports, or clinic reports. 
 For all missing dates, all missing days of the month were coded as the 1st of 
the month, and all missing months of the year were coded as January. 
 
Radiologic Response Assessment: 
 All patients who had received systemic therapy were evaluated for having 
their radiologic scans at baseline, during, and after treatment available in the 
institution’s radiology archives. Radiologic response to treatment were assessed 
using Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1 (38) using 
available images.  For the patients whose CT and/or MRIs were in the institution’s 
picture archiving and communication systems (PACS), their radiologic response to 
treatment were assessed using Response Evaluation Criteria In Solid Tumors 
(RECIST) v.1.1 and the Choi criteria. (39) 
 
Statistical Analysis: 
 Patient characteristics were summarized using medians and ranges for 
continuous variables and frequencies and percentages for categorical variables. 
The response rates and the 95% confidence interval (CI) were calculated from 
variance estimates. Fisher’s exact test was used to assess the association between 
patient or tumor characteristics and best response.  Time to best radiologic 
response was measured from the initiation of systemic therapy to development of 
Choi complete response or Choi partial response (Choi criteria) or to development 
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of RECIST complete response or RECIST partial response (RECIST). Progression-
free survival time (PFS) was defined as the time interval between the start of 
systemic therapy and radiologic evidence of disease progression (PD) as defined by 
either the Choi response criteria or RECIST, or death from any cause. Survival data 
were updated on April 1, 2010 and the patients’ data were censored at that point. 
Kaplan-Meier method was used to estimate the PFS and overall survival (OS). All 
statistical analyses were carried out in S-plus 8.0 (TIBCO Software Inc., Somerville, 
MA).  
 
 
AIM 2: To describe the activity of TMZ-BEV therapy in advanced HPC/SFT and 
identify potential clinicopathological factor(s) that correlate with response to therapy 
and outcome  
 
Patient selection: 
 The medical records of all patients with the histologic diagnoses of HPC or 
SFT treated with the temozolomide-bevacizumab combination therapy at The 
University of Texas M. D. Anderson Cancer Center through June 2007 were 
retrospectively reviewed. All patients were initially identified from the soft tissue 
tumor pathology database at the M. D. Anderson Cancer Center. The clinical 
records of the selected patients were then reviewed using the institutional electronic 
medical records database (ClinicStation).  All clinical encounters available in the 
database, as well as all available outside records which had been scanned into the 
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system, were reviewed.  Patients for whom radiologic scans were unavailable for 
radiologic response assessment were excluded from the analysis.  The following 
data on patient and disease characteristics were collected: age, sex, and ethnicity; 
disease characteristics, including primary tumor site and extent of disease; previous 
treatment and responses; toxic effects of temzolomide and bevacizumab; and 
survival. This study was approved by our institutional review board. 
 
Radiologic Assessment: 
 Baseline radiologic studies had been performed up to 4 weeks prior to the 
initiation of chemotherapy and follow-up scans had been performed every 8 to 12 
weeks. Contrast-enhanced computed tomography (CT) or magnetic resonance 
imaging (MRI), was used at the discretion of the treating physician. Radiologic 
tumor response was determined as described below. 
 Tumor size. The longest cross-sectional dimension for each measurable 
lesion was measured at the start of therapy and on each follow-up study.  The sum 
of the longest selected measurable lesions at each timepoint was computed for 
each patient. Radiologic response was then determined by calculating the absolute 
and percentage change from the baseline sum.  
 Tumor density (CT attenuation coefficient). In patients whose responses 
were assessed with contrast-enhanced CT scans, the tumor density of each lesions 
was measured in Hounsfield units (HU) by drawing a region of interest around the 
margin of the entire lesion. In patients who had CTs with triphasic techniques, tumor 
density was measured on scans obtained in the portal venous phase. The mean 
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baseline tumor density was compared with the mean tumor density on the 
subsequent studies. 
 
Response Assessment: 
 Using the Choi response criteria, a complete response (CR) was defined as 
the disappearance of all lesions without the appearance of new lesions. A Choi 
partial response (PR) was defined as a ≥10% decrease in the sum of the target 
lesions or a ≥15% decrease in tumor density in the absence of new lesions or 
obvious progression of nonmeasurable disease. Choi progressive disease (PD) was 
defined as a ≥10% increase in tumor size in the absence of favorable tumor density 
change required to achieve Choi PR. Patients whose disease did not meet the 
criteria for Choi CR, PR, or PD and who did not have tumor-related symptomatic 
deterioration were classified as having stable disease (SD).  Only the best response 
for each patient was used in determining response rate. Response was also 
assessed using Response Evaluation Criteria in Solid Tumors (RECIST) to 
compare to Choi responses. 
 
Pathology Review: 
 All tumor specimens had been reviewed by an M. D. Anderson sarcoma 
pathologist who established the diagnoses of HPC or SFT at the time of the 
patients’ initial presentation to our institution.  For the purpose of this study, two 
sarcoma pathologists who were blinded to the patients’ outcome re-reviewed all the 
available specimens to confirm the diagnoses. Histopathologic variables including 
17 
 
size, number of mitoses, cellularity, pleomorphism, and presence of necrosis and/or 
hemorrhage, were noted during the re-review if possible. Tumors were sub-
categorized as benign, malignant, or unknown and classified according to the 2002 
WHO disease classification criteria for sarcomas.  
 
Statistical Analysis: 
 Patient characteristics were summarized using medians and ranges for 
continuous variables and frequencies and percentages for categorical variables. 
The response rates and the 95% confidence interval (CI) were calculated from 
variance estimates. Fisher’s exact test was used to assess the association between 
patient or tumor characteristics and best response.  Time to best radiologic 
response was measured from the initiation of temozolomide and bevacizumab 
therapy to development of Choi complete response or Choi partial response. 
Progression-free survival time (PFS) was defined as the time interval between the 
start of temozolomide and bevacizumab therapy and radiologic evidence of PD as 
defined by either the Choi response criteria or the RECIST criteria, or death from 
any cause. Survival data were updated on October 15, 2009 and the patients’ data 
were censored at that point. Kaplan-Meier method was used to estimate the PFS 
and overall survival (OS). All statistical analyses were carried out in S-plus 8.0 
(TIBCO Software Inc., Somerville, MA).  
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AIM 3: To design a prospective phase II trial to determine the efficacy of TMZ-BEV 
regimen in locally advanced, recurrent, and metastatic HPC/SFT. 
 
The protocol was written in the format of National Cancer Institute’s Cancer 
Therapy Evaluation Program (CTEP) Phase II Protocol Submission form and 
modified .  Templates can be found at http://ctep.cancer.gov/forms. 
 
Primary Objectives: 
1) To better estimate the overall response rate (ORR) for patients with unresectable 
or metastatic HPC/SFT receiving the combination of temozolomide and 
bevacizumab using the Choi criteria. 
2) To assess the safety and tolerability of the combination of temozolomide and 
bevacizumab in patients with unresectable or metastatic HPC/SFT. 
 
Secondary Objectives: 
1) To better estimate the ORR and disease control rate (DCR) for patients with 
unresectable or metastatic HPC/SFT receiving the combination of temozolomide 
and bevacizumab using RECIST. 
2) To determine the time to progression (TTP) in patients with unresectable or 
metastatic HPC/SFT receiving the combination of temozolomide and bevacizumab 
using the Choi criteria and RECIST. 
3) To determine the relationship between best response and TTP, as assessed by 
Choi and RECIST. 
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Primary Endpoints: 
1) Overall response rate (ORR), defined as the sum of complete response (CR) and 
partial response (PR) rates as assessed by the Choi criteria. 
2) Safety and toxicity profile, as assessed by NCI CTCAE version 4.  
 
Secondary Endpoints: 
1) Overall response rate (ORR) as assessed by RECIST. 
2) Disease control rate (DCR), defined as the sum of complete response (CR), 
partial response (PR), and stable disease (SD) for the period of 6 months, assessed 
using RECIST. 
3) Time to progression (TTP), as assessed by the Choi criteria. 
4) Time to progression (TTP), as assessed by RECIST. 
 
Patient Selection: 
1. Disease characteristics: 
Inclusion criteria:  
a. Diagnosis of HPC/SFT, histologically confirmed by a central 
pathologist at M. D. Anderson Cancer Center: 
i. unresectable disease, primary or recurrent 
ii. metastatic disease 
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b. Measurable disease, defined as at least one lesion that can be 
measured in at least one dimension as ≥ 20 mm (or ≥ 10 mm of the 
CT slice thickness is ≥ 5 mm)  
i. measurable lesion must not have been irradiated ≤ 6 months 
before start of therapy. 
c. Must have 1 paraffin block of primary tumor and/or metastatic tissue 
available prior to starting therapy 
2. Prior treatment characteristics: 
a. Prior surgical resection is allowed, if measurable residual disease is 
present. 
3. Patient characteristics: 
a. Age ≥ 18 years and life expectancy of ≥ 6 months 
b. ECOG performance status of 0-2 
c. ANC ≥ 1,500 cells/microliter, Hgb ≥ 9 g/dl, Platelet count ≥ 125,000 
cells/microliter 
d. Serum creatinine ≤ 1.5 mg/dl, serum ALT, AST, total bilirubin ≤ 1.5 x 
ULN 
e. Signed informed consent approved by IRB prior to patient entry 
f. If sexually active, patients must take contraceptive measures for the 
duration of treatments 
 
1. Prior treatment characteristics: 
Exclusion criteria: 
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a. Prior history of systemic chemotherapy 
b. Prior radiation treatment ≤ 6 months prior to starting therapy 
2. Patient characteristics:  
a. Known history of hypersensitivity to dacarbazine 
b. History of HIV infection 
c. Pregnant or breastfeeding 
d. Active infection requiring IV antibiotics or antifungal medications 
e. Inadequately controlled hypertension 
f. Any prior history of hypertensive crisis/ hypertensive encephalopathy 
g. ≥ Grade II New York Heart Association congestive heart failure 
h. History of myocardial infarction/ unstable angina < 6 months prior to 
enrollment 
i. Serious cardiac arrhythmia (i.e. ventricular arrhythmia, high-grade 
atrioventricular block) that requires medication during the study, 
interferes with regularity of the study treatment, or is uncontrolled by 
medications 
j. History of stroke/ TIA < 6 months prior to study enrollment 
k. Significant vascular disease 
l. Symptomatic peripheral vascular disease 
m. Evidence of bleeding diathesis/ coagulopathy with INR > 1.5 
n. Major surgical procedure, open biopsy, significant traumatic injury < 4 
weeks prior to enrollment 
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o. Core biopsy/ other minor surgical procedure, excluding placement of 
vascular access device < 7 days prior to enrollment 
p. History of abdominal fiscula, GI perforation, intra-abdominal abscess < 
6 months prior to enrollment 
q. Serious, non-healing wound, active peptic ulcer or non-healing bone 
fracture 
r. Proteinuria ≥ 2+ by urine dipstick OR urine protein > 1g by 24-hour 
urine collection 
s. History of other primary tumors within the past 5 years, except 
adequately controlled limited basal cell or squamous cell skin cancer 
or carcinoma in situ of the cervix. 
t. Presence of frequent vomiting or any other pre-existing medical 
condition that would preclude swallowing and/or absorption of oral 
medication. 
u. Evidence of any psychological dysfunction, psychiatric disorder, giving 
reasonable suspicion of a disease or condition that contraindicates the 
use of therapy, or that may affect patient compliance with study 
routines, or places the patient at high risk from treatment-related 
complications. 
 
Treatment Plan: 
This protocol will utilize a single arm, phase II design.  All patients will receive 
temozolomide orally at 150 mg/m2 daily on days 1-7 and 15-22 on a 1 week-on, 1 
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week-off schedule in a 28-day cycle. Bevacizumab will be delivered intravenously at 
10 mg/kg on days 8 and 22.  Patients will continue on treatment until disease 
progression, severe toxicity, or if the patient’s physician felt that it was not in the 
patient’s best interest to continue.  A patient may discontinue treatment for an 
intercurrent illness that prevented further treatment administration, if the patient 
decides to withdraw from the study. 
The dosing schema and route are illustrated below: 
Table 1. Temozolomide-bevacizumab administration schema 
REGIMEN DESCRIPTION 
 
Agent 
 
Dose 
 
Route 
 
Schedule 
Cycle 
Length  
Temozolomide 150 mg/m2 
in  
tablets 
PO in the 
a.m. 
Days 1-7, 
15-21 4 weeks (28 
days) 
 Bevacizumab 5 mg/kg IV over 90, then 60 
minutes 
Days 8, 
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Dose reductions in temozolomide are allowed, and will occur in the following 
manner: 
 
 Table 2. Dose reduction guidelines for temozolomide therapy 
Toxicity Reduce TMZ by 1 
Dose Level 
Discontinue 
TMZ 
Absolute Neutrophil Count < 1.0 x 109/L See below 
Platelet Count < 50 x 109/L See below 
CTC non-hematolotical 
toxicity (except for alopecia, 
nausea, vomiting) 
CTC grade 3 CTC grade 4 
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Dose Level Temozolomide Dose 
(mg/m2/day) 
Remarks 
-2 75 Second reduction 
for toxicity  
-1 125 Reduction for 
toxicity  
0 150 Initial dose 
 
 
TMZ is to be discontinued if dose reduction to < 75 mg/m2 is required or if the same 
Grade 3 non-hematological toxicity (except for alopecia, nausea, vomiting) recurs 
after dose reduction. For the treatment of nausea and vomiting associated with 
temozolomide, patients will be prescribed antiemetic agents as necessary for 
symptom control.  Pain medications will also be prescribed as needed.  In the cases 
of grade 3 or 4 hematological toxicities, the use of hematopoietic growth factors will 
be determined on an individual case base by the Principle Investigator. 
 
Pretreatment Evaluation: 
Evaluation before initiating treatment with temozolomide and bevacizumab 
will include the following: 
• Complete history and physical examination, including documentation of all 
measurable disease as well as signs, symptoms, concurrent medications, 
and performance status. 
• Laboratory studies:  CBC with differential, sodium, potassium, chloride, 
bicarbonate, BUN, creatinine, glucose, calcium, magnesium, albumin, 
alkaline phosphatase, total bilirubin, SGOT[AST], SGPT[ALT], PT/PTT, 
urinalysis, serum pregnancy test (women of childbearing potential). 
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• 12-lead EKG within 28 days prior to starting treatment. 
• Radiologic evaluation of measurable disease  
• Optional serum samples for evaluation of angiogenesis-related markers, 
including but not limited to VEGF, IL-8, IL-12, PIGF, bFGF, PDGF, and 
hypoxia-inducible factor at the start of treatment. 
• Patient must sign IRB-approved informed consent prior to any study-specific 
procedures unless such procedures are part of the standard of care. 
 
Evaluation During Study: 
Evaluation once after initiating treatment will include the following (see also the 
previous table):  
• Physical examination (including vital signs, weight, performance status): 
before week 1 of each cycle prior to starting the next cycle.   
• Labs prior to day 1 1 of each cycle: CBC with differential, sodium, potassium, 
chloride, bicarbonate, BUN, creatinine, glucose, calcium, magnesium, 
albumin, alkaline phosphatase, total bilirubin, SGOT [AST], SGPT [ALT].  
Urinalysis prior to day 1 of each cycle. 
• Radiologic evaluations will be repeated after 2 cycles of treatment.  The 
same radiologic method of assessment and the same technique should be 
used to characterize each identified and reported lesion at baseline and 
during follow-up. 
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• For the patients who underwent pretreatment serum studies, additional 
serum will be analyzed during weeks 8-12 of treatment, then at the time of 
disease progression or at the end of the treatment, whichever is earlier. 
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Table 3. Study calendar: TMZ-BEV therapy 
   
 
Pre- 
Study 
 
Wk 
1 
 
Wk 
2 
 
Wk 
3 
 
Wk  
4 
 
Wk 
5 
 
Wk 
6 
 
Wk 
7 
 
Wk 
8 
 
Wk 
9 
 
Wk 
10 
 
Wk 
11 
 
Wk 
12 
S
chedule repeated until an endpoint is m
et 
 
Off 
Study
c
 
Temozolomide 
 
 
 
T 
 
 
 
T 
 
 
 
T 
 
 
 
T 
 
 
 
T 
 
 
 
T 
 
  
 
Bevacizumab 
 
 
 
 
 
B 
 
 
 
B 
 
 
 
B 
 
 
 
B 
 
 
 
B 
 
 
 
B  
 
Informed consent 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Demographics 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Medical history 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Concurrent meds 
 
X 
 
X-------------------------------------------------------------------------------------------------X  
 
Physical exam 
 
X 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
  X 
 
Vital signs 
 
X 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 X 
 
Height 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Weight 
 
X 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 X 
 
Performance 
status 
 
X 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 X 
 
CBC w/diff, plts 
 
X 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
  
 
Serum chemistry
a
 
 
X 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
  
 
EKG (as indicated) 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Adverse event 
evaluation 
 
 
 
X-------------------------------------------------------------------------------------------------X X 
 
 
Tumor 
measurements 
 
 
X 
 
Tumor measurements are repeated every 8 weeks.  Documentation 
(radiologic) must be provided for patients removed from study for 
progressive disease. 
X
c
 
 
Radiologic 
evaluation 
 
X 
 
Radiologic measurements should be performed every 8 weeks. X
c
 
 
B-HCG 
 
X
b
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
A: CTEP IND Agent
B: 
:  Dose as assigned; administration schedule 
Other Agent(s)
a: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus, 
potassium, total protein, SGOT [AST], SGPT [ALT], sodium. 
:  Dose as assigned; administration schedule 
b: Serum pregnancy test (women of childbearing potential). 
c: Off-study evaluation.   
 
 
Evaluation of Toxicity 
Toxicities will be described according to the NCI-CTCAE Version 4.0.  Dose limiting 
toxicity (DLT) was defined as any grade 3 or 4 non-hematologic toxicity as defined 
in the NCI CTC v4.0, even if expected and believed related to the study medications 
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(except nausea and vomiting responsive to appropriate regimens or alopecia), any 
Grade 4 hematologic toxicity lasting 2 weeks or longer (as defined by the NCI-
CTCAE), despite supportive care; any Grade 4 nausea or vomiting > 5 days despite 
maximum anti-nausea regimens, and any other Grade 3 non-hematologic toxicity 
including symptoms/signs of vascular leak or cytokine release syndrome; or any 
severe or life-threatening complication or abnormality not defined in the NCI-CTCAE 
that is attributable to the therapy.   
 
Criteria for Response 
 For the purposes of this study, patients should be re-evaluated for response 
every 8 weeks.  In addition to a baseline scan, confirmatory scans should also be 
obtained not less than 4 weeks following initial documentation of objective 
response, i.e. CR or PR as defined by the Choi criteria. 
 Response and progression will be evaluated in this study using the Choi 
criteria. (39) Like the RECIST criteria, changes in only the largest diameter 
(unidimensional measurement) of the tumor lesions are used to calculate change in 
size.  In addition, changes in CT attenuation coefficient (density) of the tumor will be 
evaluated in Hounsfield Units (HU).  A mean HU for each tumor density will be used 
to calculate percent changes in CT density. The definition for CR, PR, SD, and PD 
for Choi criteria for best response assessment is illustrated in Table 4: 
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Table 4. Summary of the Choi criteria definitions 
Response Definitions 
CR Disapperance of all lesions 
No new lesions 
PR A decrease in size of ≥ 10% or a decrease in tumor density 
(HU) ≥ 15% on CT 
No new lesions 
No obvious progression of nonmeaserable disease 
SD Does not meet the criteria for CR, PR, or PD 
No symptomatic deterioration attributed to tumor progression 
PD All increase in tumor size of ≥ 10% and does not meet criteria of 
PR by tumor by tumor density (HU) on CT 
New lesions 
New intratumoral nodules or increase in the size of the existing 
intratumoral nodules 
 
 Response and progression will also be assessed in this study using the new 
international criteria proposed by the Response Evaluation Criteria in Solid Tumors 
(RECIST) Committee. (38) Changes in only the largest diameter (unidimensional 
measurement) of the tumor lesions are used in the RECIST criteria. 
 The best overall response (ORR) is the best response recorded from the 
start of the treatment until disease progression/recurrence (taking as reference for 
progressive disease the smallest measurements recorded since the treatment 
started).  The patient's best response assignment will depend on the achievement 
of both measurement and confirmation criteria. 
  The duration of overall response is measured from the time measurement 
criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for 
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progressive disease the smallest measurements recorded since the treatment 
started). 
 The duration of overall CR is measured from the time measurement criteria 
are first met for CR until the first date that recurrent or progressive disease is 
objectively documented. 
  The duration of disease control response (DCR) is measured from the time 
measurement criteria are met for CR, PR, or SD (whichever is first recorded) until 
the first date that recurrent or progressive disease is objectively documented (taking 
as reference for progressive disease the smallest measurements recorded since the 
treatment started).  This will be considered censored if the patient is lost to follow-up 
or dies of a cause unrelated to the disease under study prior to the ascertainment of 
progressive disease. 
   Stable disease (SD) is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements 
recorded since the treatment started. This will be considered censored if the patient 
is lost to follow-up or dies of a cause unrelated to the disease under study prior to 
the ascertainment of progressive disease 
   Time to progression (TTP) is defined as the duration of time from start of 
treatment to time of disease progression, death secondary to disease or toxicity of 
treatment, or date of last follow-up.  Patients who have not demonstrated 
progressive disease or have died because of disease or toxicity will be considered 
censored for this outcome at the last contact. 
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Criteria for Removal from Study 
Patients will be discontinued from treatment on the study for any of the following 
events: 
• Progression of disease per Choi criteria as described previously.  
• The development of unacceptable toxicity. 
• Physician recommendation for patient removal. 
• Patient elects to discontinue further treatment on the study medications. 
 
Statistical Considerations: 
Any patient who completes two (2) or more cycles of therapy and 
demonstrates CR or PR as per the Choi criteria will be considered for evaluation of 
the primary efficacy endpoint of Choi ORR. Patients who demonstrate CR or PR as 
assessed by the Choi criteria after cycle 2 and beyond will be considered as 
“responders” for the purposes of the evaluation rule below.  All other response-
evaluable patients will be considered “non-responders”.  Patients who are removed 
from protocol therapy prior to cycle 2 because of toxicity will be considered non-
responders for the purposes of the study endpoint.  Patients who are removed from 
protocol therapy prior to cycle 2 for reasons other than disease progression or 
toxicity will be replaced. 
 Any patient who completes at least four cycles of therapy and demonstrates 
RECIST CR, RECIST PR, or maintains SD through cycle 4 will be considered for 
evaluation of the primary efficacy endpoint of disease control rate (DCR).   Patients 
who demonstrate RECIST CR, RECIST PR, or maintains SD through cycle 4 will be 
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considered as “responders”. Patients who experiences PD before the fourth cycle of 
therapy also will be considered and will be considered as “non-resonders” All other 
patients will be considered non-responders.  Time to progression will be calculated 
using both the RECIST and the Choi criteria.  Time to progression (RECIST) and 
time to progression (Choi) will then be analyzed according to the responders and 
the non-responders, as previously defined by each criteria.  Kaplan-Meier curves 
will be constructed for each of the outcome measures. (40)   
A minimum of 8 patients and a maximum of 30 patients will be enrolled. We 
will monitor the trial continuously using Bayesian methodology.  Denote the overall 
response rate (ORR) by pR and the toxicity rate by pT.  We consider an overall 
response rate of less than 35% not clinically meaningful and an overall response 
rate of 50% or greater would warrant further development. Therefore, we assume a 
priori that the ORR has a mean of 0.35 and pR ~ Beta(0.7, 1.3).   The expected 
toxicity rate is 20% and thus pT ~ Beta(0.4, 1.6) which has a mean of 0.2.  A toxicity 
rate of 30% or greater is considered unacceptable.     We will stop the trial for lack 
of activity if Pr(pR < 0.5 | data ) < 0.99.  That is, if it is very unlikely that we have 
reached the target response rate of 50% then we will stop the trial for lack of 
activity.  We will stop the trial for excessive toxicity if Pr(pT > 0.3 | data ) > 0.8.  The 
resulting stopping rules are provided in Tables 5 and 6.  
In order to obtain the design’s operating characteristics the trial was 
simulated and the results are provided in Table 7. The goal of the design is to have 
a high likelihood of stopping when a drug is too toxicity or has a low ORR.  The 
scenarios listed in red indicated that the drug is either too toxic or has a lack of 
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activity.  In scenario 1, the ORR is 60% and the toxicity is 20% and there is only at 
10% chance that we will incorrectly stop the trial.  However, in scenario 6 the ORR 
is 25% and the toxicity rate is 30% and due to the lace of activity and unacceptable 
toxicity rate the trial is stopped early 88% of the time and on average 15 patients 
are enrolled.  In general, the lower the ORR or the higher the toxicity rate the more 
likely it is that the trial will be stopped early. 
 
Table 5: Response stopping boundaries 
The following are less-than-or-equal boundaries: a pair (n, m) means to stop if the 
number of responses after treating m patients is less than or equal to n. 
n  (# responses) m  (# patients) 
0 8 
1 9 
2 12 
3 15 
4 18 
5 20 
6 23 
7 26 
8 28 
9 30 
 
Table 6: Toxicity stopping boundaries 
The following are greater-than-or-equal boundaries:  a pair (n, m) means to stop if 
the number of toxicities after treating m patients is greater than or equal to n. 
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n  (# toxicities) m  (# patients) 
8 8 
7 8 
6 8 
5 8 
4 8 
5 10 
6 12 
6 13 
7 15 
7 16 
8 18 
8 19 
9 21 
9 22 
10 24 
10 25 
11 27 
11 28 
12 30 
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Table 7: TMZ-BEV study: simulation results 
Response rates in bold have indicate scenarios where the ORR has failed to 
reach an acceptable level and true toxicity rates in red indicate scenarios where 
the toxicity rate is too high. 
 
Scenario True 
pR 
True 
pT 
Pr 
(Stop 
Early ) 
Avg. 
# 
Pts. 
Avg. # of 
Respons
es 
Avg. #  
Toxicity 
Avg. 
Trial 
Duration 
(Months) 
1 0.60 0.20 0.09 28 17 6 21.2 
2 0.50 0.20 0.14 28 14 6 20.9 
3 0.50 0.30 0.40 23 11 7 17.7 
4 0.35 0.20 0.47 23 8 5 17.7 
5 0.35 0.30 0.63 20 7 6 15.3 
6 0.25 0.30 0.88 15 4 5 8.4 
7 0.20 0.30 0.96 13 3 4 7.1 
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Chapter 3 
RESULTS 
 
AIM 1: To estimate the overall response rate (ORR) and progression-free survival 
(PFS) of advanced HPC/SFT patients who were treated systemic chemotherapy, 
especially those with doxorubicin-based, gemcitabine-based or paclitaxel-based 
chemotherapy 
 
Patient and Disease Characteristics 
 Five hundred and fifty-three patients with the diagnosis of HPC/SFT whose 
pathology specimens were evaluated that The University of Texas MD Anderson 
Cancer Center between January 1993 to June 2007 were identified.  They were 
then evaluated for available clinical medical records at MD Anderson.  Four hundred 
twenty-three patients were excluded, and the remaining 128 patients were 
analyzed. (Figure 1)  The patients’ characteristics are summarized in Table 8.   
Patients were analyzed based on the disease status at which they first presented at 
MD Anderson.  Patient characteristics of all patients who presented with primary 
localized HPC/SFT are summarized in Table 9.  Patient characteristics of all 
patients who presented with locally recurrent and/or metastatic HPC/SFT are 
summarized in Table 13. 
 
 
 
37 
 
Figure 1. Evaluation schema for identification of evaluable HPC/SFT patients 
 
 
Table 8. HPC/SFT patient characteristics: all patients 
Characteristic (N=128) (%) 
Age at First MDACC registration  
median 54 years 
range 19 – 88 years 
Gender  
male 71 55.5 
female 47 44.5 
Ethnicity  
White 101 78.9 
Hispanic 17 13.3 
Black 4 3.1 
Asian 6 4.7 
Primary tumor site   
CNS/meninges 39 30.5 
Head/neck 13 10.2 
lung/pleura 17 13.3 
Abdomen/pelvis 36 28.1 
Extremities 15 11.7 
Other 6 4.7 
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HPC/SFT – Primary Localized Disease 
 Seventy-nine patients who presented to MD Anderson with primary localized 
disease were analyzed.  Consistent with reports in the literature, the sites of primary 
disease were divided evenly throughout diverse body sites, with the abdominopelvic 
cavity as the most common site.  Almost all patients received surgical resection as 
their initial therapy.  For the seventy-two patients who received surgery, most 
patients had gross total resection (GTR) of their primary disease.  Thirty-six (46%) 
patients also received additional radiation therapy either as neoadjuvant or adjuvant 
therapy.  Ten (13%) patients also received chemotherapy either in neoadjuvant or 
adjuvant fasion.  For the seven patients who were not deemed surgically resectable, 
they received palliative radiation therapy (n=1), chemotherapy (n=1), or both (n=5). 
The treatment histories are summarized in Table 10. 
 
Table 9. HPC/SFT patient characteristics: primary localized HPC/SFT 
 
 
 
 
 
 
 
 
 
Variable Median (range) N (%)
N 79
Age 51 (19 - 86)
Sex
Male 34 (43)
Female 45 (57)
Primary Tumor Site
CNS/meninges 20 (25)
Head and Neck 12 (15)
Lung/Pleura 10 (13)
Abodmen/Pelvis 23 (29)
Extremities 12 (15)
Other 2 (3)
39 
 
Table 10. Treatment: primary localized HPC/SFT 
 
 
 
 
 
 
 
 
 The majority of the HPC/SFT patients had a favorable clinical course, similar 
to previously described cases in the literature. (Table 11) The median follow-up 
period for the cohort following surgical resection was 45.4 months (range, 0.1 – 
198.8 months). Fifty-three (67%) patients were recurrence-free at the time of this 
analysis.  Median recurrence free survival for the cohort was 126 months, or 10.5 
years (Figure 2)  Univariate analysis showed that age and tumor size were the only 
significant variables for predicting recurrence-free survival (RFS). (Table 12) 
Table 11. Clinical outcome: primary localized HPC/SFT 
 
 
N = 79 %
Initial Treatment - surgery
No 7 9
Yes 72 91
Complete resection
GTR 26 33
R0 37 47
R1 6 7
Incomplete resection (R2) 3 4
Unknown 7 9
Initial Treatment - Radiation Therapy
Neoadjuvant Rx 14 18
Adjuvant Rx 22 28
Initial Treatment - Chemotherapy
Neoadjuvant Rx 8 10
Adjuvant Rx 2 3
N = 79 %
Disease recurrence (for resected pts)
Yes
Local 12 15
Metastatic 13 16
Local & Metastatic 3 4
No
Median Recurrence Free Survival (months) 126
Median Overall survival (months) 155
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Figure 2. Recurrence-free survival curve: primary Localized HPC/SFT 
 
 
 
 
 
 
 
 
 
Table 12. Univariate analysis for RFS: Primary localized HPC/SFT 
 
 
Variable Coefficient SE Hazard Ratio P-value
Age 0.03 0.01 1.03 0.02
Gender = Male (vs. Female) -0.41 0.41 0.66 0.31
Tumor size (cm) 0.07 0.02 1.07 0.002
Tumor site = Extremities (vs. others) -1.72 1.03 0.18 0.10
Tumor site = CNS (vs. others) -0.37 0.49 0.69 0.45
Tumor site = Head & Neck (vs. others) -1.18 0.76 0.31 0.12
Type of resection = R2 or unkonwn  (vs. R0/R1/GTR) 0.20 1.04 1.23 0.85
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HPC/SFT – Locally Recurrent and Metastatic Disease 
 The patient characteristics of the 49 HPC/SFT patients who presented to MD 
Anderson with locally recurrent and/or metastatic disease are summarized in Table 
13. The most common site of metastases was liver (n=15), followed by bone (n=12) 
and lung (n=8).  Surgical resection remained the initial treatment of choice for the 
majority of the patients, and the many of them were able to undergo successful 
surgical resection.  The use of additional treatment modalities, i.e. radiation therapy 
and/r chemotherapy were noted more frequently, with 43% of patients undergoing 
systemic therapy either as adjuvant or neoadjuvant fashion.  Despite these 
treatment, however, the duration of remission after their initial management at MD 
Anderson was relatively short, with the median PFS of 18 months.  (Figure 3)  Many 
patients subsequently underwent many additional courses of various therapies 
including additional surgical resection, radiation therapy, and/or systemic therapy, 
which is reflected by the relatively long median overall survival of 55 months (Figure 
4), from the time of their initial treatment at MD Anderson. 
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Table 13. HPC/SFT patient characteristics: locally recurrent and metastatic 
HPC/SFT 
 HPC/SFT 
 
 
 
Table 14. Treatment: locally recurrent and metastatic HPC/SFT 
N = 49 %
Surgery
Curative Intent
complete resection (R0/R1/GTR/unknown) 43 87
Incomplete resection (R2) 6 13
Radiation Therapy
Adjuvant/Neoadjuvant Rx 9 18
Palliative 2 4
Chemotherapy  
Adjuvant/Neoadjuvant Rx 21 43
Palliative 0 0
Median progression-free survival 18 months
43 
 
Figure 3. Progression-free survival curve from time of treatment: locally recurrent 
and metastatic HPC/SFT 
 
 
 
 
 
 
 
 
 
 
Figure 4. Overall survival from time of treatment: locally recurrent and metastatic 
HPC/SFT 
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Systemic chemotherapy in primary unresectable, locally recurrent, and/or 
metastatic HPC/SFT 
 Thirty-eight patients with gross, measurable disease received systemic 
chemotherapy for the management of advanced disease.  The majority of the 
patients had these that were deemed surgically unresectable, while 4 patients had 
advanced disease that were potentially surgical resectable who received 
chemotherapy in a neoadjuvant fashion to best reduce the size of tumors prior to 
surgery.  Fifteen patients received Adriamycin-based chemotherapy; 4 patients 
received gemcitabine-based chemotherapy, while 4 patients received paclitaxel 
therapy.  All received therapy either in the first- or second-line setting.  Their 
responses to therapy, reason for discontinuation of therapy and time to progression 
(TTP) are summarized in Table 15 and Figure 5.  The median PFS for the systemic 
chemotherapy cohort was 4.6 months (range, 1.3 - 15.7).  For the 14 patients who 
received combination therapy of temozolomide and bevaciuamb, their patient 
characteristics and clinical outcome are described in detail in Aim 2. 
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Table 15. Systemic therapy in advanced HPC/SFT 
Characteristic (N=23) (%) 
Chemotherapy  
Adriamycin-based Rx 15 52 
Adriamycin + ifosfamide 12  
Adriamycin + DTIC 1  
Adriamycin + cisplatin 1  
Adriamycin 1  
Gemcitabine-based Rx 4 14 
Gemcitabine + Docetaxel 1  
Gemcitabine 3  
Paclitaxel 4 14 
   
Stage   
Primary locally advanced 3 13 
Locally recurrent 1 4 
Metastatic 19 83 
   
Line of Therapy   
First-line 18 78 
Second-line 5 22 
   
Number of cycles given   
Median 4 
Range 2-10 
   
Reason for Stopping Therapy   
Disease Progression 11 48 
Toxicities 5 22 
Treatment break 3 13 
Surgical consolidation 3 13 
XRT consolidation 1 4 
   
Best Response (RECIST)  
CR/PR 0 0 
SD  19 86 
PD 4 14 
Time-to-progression   
Median 4.6 
Range 1.3-15.7 
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Figure 5. Time-to-progression curve: systemic therapy in advanced HPC/SFT 
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AIM 2: To describe the activity of TMZ-BEV therapy in advanced HPC/SFT and 
identify potential clinicopathological factor(s) that correlate with response to therapy 
and outcome  
 
Patient and Disease Characteristics 
 Sixteen patients with advanced, recurrent, or metastatic HPC/SFT who 
received temozolomide-bevacizumab therapy between May 2005 and June 2007 
were identified.  Two patients for whom radiologic scans were missing were 
excluded from the analysis. The remaining 14 patients’ characteristics are 
summarized in Table 8. All 14 patients (9 men, 5 women) were white, and the 
median age was 59 years (range, 44 – 75 years). Ten patients (71%) had HPC and 
4 patients (29%) had SFT. The most common site of primary disease was the 
meninges (n=6). Seven patients had metastatic disease when they began 
temozolomide-bevacizumab therapy, while the remaining patients had either 
primary or locally recurrent disease deemed surgically unresectable. 
The majority of the patients (86%) had received prior therapy before starting 
treatment with temozolomide and bevacizumab (Table 8). Five patients had 
received prior systemic therapy (Table 9). Their best responses to each prior 
regimen were re-assessed using the Choi criteria. They had often achieved SD and 
improvement in their symptoms with the previous regimens, but none had achieved 
Choi PR. The main reasons for starting temozolomide-bevacizumab therapy 
included symptomatic disease, neoadjuvant treatment to potentially downstage the 
tumor and enable surgical resection, and disease progression after prior therapy. 
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Table 16. TMZ-BEV therapy: patient and disease characteristics 
Characteristic (N=14) (%) 
Age  
median 59 years 
range 44 – 75 years 
Gender  
male 9 64.3 
female 5 35.7 
Ethnicity  
white 14 100 
Diagnosis  
HPC 10 71.4 
SFT 4 28.6 
Primary tumor site   
meninges 6 42.9 
lung/pleura 3 21.4 
pelvis 3 21.4 
abdominal wall 1 7.1 
gluteal region 1 7.1 
Tumor classification at diagnosis  
benign 3 21.4 
malignant  5 35.7 
unknown 6 42.9 
Metastatic disease  
no 7 50.0 
yes 7 50.0 
Prior therapy  
no 2 14.3 
yes 12 85.7 
Number of prior surgeries   
0 4 28.6 
1 3 21.4 
2 3 21.4 
3 2 14.3 
4 1 7.1 
6 1 7.1 
Prior radiation therapy  
no 7 50.0 
yes 7 50.0 
Number of prior systemic therapies  
0 9 64.3 
1 1 7.1 
2 1 7.1 
3 1 7.1 
4 1 7.1 
5 1 7.1 
Abbreviations: HPC, hemangiopericytoma; SFT, solitary fibrous tumor. 
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Table 17. TMZ-BEV therapy: patients’ prior systemic therapy history 
Tumor Prior regimen(s) 
Duration 
of therapy 
(months) 
Best response 
(Choi) 
Reason for stopping 
therapy 
SFT Gemcitabine-docetaxel 2 PD Disease progression 
SFT Gemcitabine-docetaxel 1 PD Disease progression 
Doxorubicin-dacarbazine 3 SD Disease progression 
HPC Imatinib 5 SD Disease progression 
Imatinib-thalidomide 1 PD Disease progression 
Imatinib-thalidomide-etoposide 1 SD Toxicities 
Patient intolerance 
Imatinib-thalidomide-hydrea 7 SD Disease progression 
Imatinib-hydrea 2.5 SD Disease progression 
HPC Celecoxib* 14 SD* Disease recurrence 
Imatinib 2 PD Disease progression 
Paclitaxel* 6 SD* Physician decision 
Gemcitabine-docetaxel 3 SD Disease progression 
HPC Endostatin 7 PD Disease progression 
Toxicities 
Paclitaxel 8 SD Disease progression 
Gemcitabine 8 SD Disease progression 
 
* Received regimen as adjuvant therapy after R0 resection.  
 
Treatment  
All patients received temozolomide 150 mg/m2 orally on days 1-7 and days 
15-21, and bevacizumab 5 mg/kg intravenously on day 8 and day 22 on a 28-day 
cycle.  The median number of cycles given was 7.5 (range 2.5-27). Four patients 
required temozolomide dose modifications or treatment delay because of 
neutropenia (n=1) or thrombocytopenia (n=3), and one of them received 
granulocyte colony-stimulating factor support. 
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Clinical Outcome 
 The overall response rate was 79% (11 patients, 95% CI 49.2%-95.3%). All 
11 patients who responded had Choi PR (Table 10). Two patients (14%) achieved 
Choi SD, and Choi PD was the best response in 1 patient (7%). 
Response was observed as a decrease in size (n=1), in density (n=3), or in 
both (n=7). (Figure 1) Ten patients (71%) demonstrated some degree of tumor 
shrinkage; their median tumor size change was -10.1% (range -56.2%-15.5%). Ten 
patients (71%) demonstrated at least a 15% reduction in tumor density, and the 
median percent change in density was -26.2% (range -67.6%-5.4%).  For the 
patients who demonstrated a Choi PR, response was seen early during treatment, 
with all patients achieving PR after 2 to 4 cycles; the median time to response was 
2.5 months (range 1.6-4.7 months). For the seven patients who had symptomatic 
disease at the time of starting therapy, six achieved Choi PRs, which were seen 
with improvements in their symptoms. 
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Table 18. Overall response to TMZ and BEV 
Patient Tumor 
Maximum 
change in 
tumor 
size (%) 
Maximum 
change in 
density 
(%) Best response (Choi) 
Best 
response 
(RECIST) 
1 HPC -56.2 -41.3 PR ↓Size ↓HU PR 
2 SFT -42.1 -67.6 PR ↓Size ↓HU PR 
3 SFT -26.7 -16.2 PR ↓Size ↓HU SD 
4 HPC -19.5 -19.1 PR ↓Size ↓HU SD 
5 HPC -18.5 -39.4 PR ↓Size ↓HU SD 
6 SFT -13.7 -83.1 PR ↓Size ↓HU SD 
7 SFT -6.5 -23.7 PR ↓Size ↓HU SD 
8 HPC -26.9 N/A* PR ↓Size  SD 
9 HPC -6.1 -28.7 PR  ↓HU SD 
10 HPC -3.4 -60.5 PR  ↓HU SD 
11 HPC 4.9 -15.5 PR  ↓HU SD 
12 HPC 0 N/A* SD   SD 
13 HPC 4.6 4.4 SD   SD 
14 HPC 15.5 5.4 PD   SD 
           
Median  -10.1 -26.2      
Abbreviations: HPC, hemangiopericytoma; SFT, solitary fibrous tumor; PR, partial 
response; SD, stable disease; PD, progressive disease; HU, Hounsfield units. 
* Response assessment done with MRI; unable to measure density changes.  
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Figure 6. CT images demonstrating a Choi PR to TMZ and BEV in a patient 
with recurrent, unresectable SFT of pleura. Left, images show baseline disease 
at the start of therapy.  Right, images show the decrease in size and density of 
disease after 27 cycles of treatment. 
 
    
 
 
 
 The overall response rate was also calculated using the RECIST criteria. 
Two patients (14%) achieved a RECIST PR (95% CI 1.8%-42.8%). The remaining 
12 patients all achieved RECIST SD, with 11 patients (79%) demonstrating RECIST 
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SD for more than 4 months (95% CI 49.2%-95.3%). No statistically significant 
associations were found between response and any patient or tumor 
characteristics, including primary tumor location (meningeal vs. non-meningeal) and 
primary tumor histologic classification (benign vs. malignant vs. unknown). 
 At the time of analysis, the median follow-up was 34 months. The median 
Choi PFS was 9.67 months (95% CI 7.31 months-not estimable), and the proportion 
of patients who were progression-free at 6 months was 78.6% (Figure 7). The 
median RECIST PFS was 10.8 months (95% CI 8.13 months-not estimable) (Figure 
8), and the 6-month PFS was 92.9%. To date, 5 patients are alive and 4 (28.6%) of 
them remain progression-free. Ten (71.4%) patients had ultimately had PD or had 
died.  The median OS was estimated at 24.3 months. 
 
Figure 7. Kaplan-Meier estimates for progression-free survival (PFS) (Choi criteria).  
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Figure 8. Kaplan-Meier estimates for progression-free survival (PFS) (RECIST).  
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Toxicity 
  Treatment was generally well tolerated, but because it was not administered 
in a clinical trial setting, toxicity data were not recorded systematically.  The most 
notable toxic effect was myelosuppression, with neutropenia and thrombocytopenia 
requiring treatment modifications and/or delays in 4 patients. Fever, chills, fatigue, 
nausea, and headache were also noted. 
One patient developed a pulmonary infiltrate after 20.5 cycles of 
temozolomide-bevacizumab therapy, at which point therapy was withheld. A follow-
up chest CT study 6 weeks later showed a persistent lung nodule.  A biopsy of the 
lesion showed inflammation and the cultures were positive for Cryptococcus. The 
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patient was successfully treated with oral fluconazole, and the infection 
subsequently resolved. 
 One patient died during treatment.  The 48-year-old woman with a recurrent 
HPC tumor adjacent to the cervical spine had undergone 3 prior surgeries and 
radiation therapy. On day 11 of cycle 4 of temozolomide-bevacizumab therapy, she 
was admitted to the hospital with Staphylococcus aureus bacteremia secondary to 
infected hardware in her cervical spine.  She was treated with intravenous 
antibiotics and the bacteremia resolved.  She received 2 additional cycles of 
treatment but was admitted again on day 7 of cycle 6 with renal failure, altered 
mental status, and hypotension.  She died the following day. 
 
 
 
AIM 3: To design a prospective phase II trial to determine the efficacy of TMZ-BEV 
regimen in locally advanced, recurrent, and metastatic HPC/SFT. 
 
The concept of this protocol was submitted to Sarcoma Alliance for Research and 
Collaboration (SARC) consortium as a potential multi-institutional trial.  The concept 
has been accepted for submission for a full protocol proposal.  The final version of 
the protocol (the most recent version appears on the Appendix B) will be submitted 
to SARC.  Funding is being sought through Schering and/or Genentech. 
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Chapter 4 
DISCUSSION 
. 
 Currently, the combination of doxorubicin and ifosfamide is the standard 
systemic chemotherapy regimen for many subtypes of soft tissue sarcoma. 
Gemcitabine combined with docetaxel has also emerged as a good therapeutic 
choice for these patients. Although cases of HPC/SFT responding to these 
chemotherapeutic agents have been sporadically reported,(10, 16-18, 41, 42) no 
systematic review or clinical trial to date has identified an effective systemic regimen 
for unresectable HPC/SFT.  
 To better understand the impact of temozolomide and bevacizumab in 
HPC/SFT, we decided to expand our examination of the historical HPC/SFT cohort 
of patients who had received standard-of-care systemic chemotherapy.  Thus in this 
largest retrospective study of advanced HPC/SFT patients to date, we show that for 
patients who are not candidates for surgical resection, systemic chemotherapy is 
only minimally effective for the majority of the patients. Most patients did not 
achieve objective radiologic response to chemotherapy, and many progressed early 
on during treatment, as evidenced by the modest median PFS of 4.6 months.  The 
type of chemotherapy administered did not appear to make a difference in response 
or PFS, although the small number of patients examined limits us from drawing any 
more definitive conclusions. 
 In addition, the review of our temozolomide and bevacizumab HPC/SFT 
patients’ prior systemic chemotherapy regimens showed that doxorubicin, 
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gemcitabine-docetaxel, and paclitaxel did not produce a radiologic response in any 
of the 5 patients. Since their responses had been initially determined by RECIST, 
we retrospectively re-assessed their responses using the Choi criteria, and 
concluded that none of the patients had achieved a Choi PR to prior therapy, but all 
5 had a PR to temozolomide and bevacizumab. 
 The activity of temozolomide and bevacizumab in advanced HPC/SFT 
observed in this retrospective review, therefore, seems to be much more favorable 
than that with standard chemotherapy regimens. In patients with locally advanced, 
recurrent, or metastatic HPC/SFT who were treated with temozolomide and 
bevacizumab, reductions in tumor size and/or density consistent with PRs as 
assessed by the Choi criteria were evident in most patients. Several patients also 
demonstrated long periods of freedom from disease progression, with 5 patients 
having a time-to-progression period of ≥20 months. Our study has the typical 
limitations of a retrospective analysis, including the possibilities of patient selection 
bias and observer bias, a small sample size, and the lack of a systematic, 
comprehensive recording of toxicities. Nevertheless, the degree of radiologic 
responses and the long duration of PFS observed in out patients appear superior to 
those observed in historical studies with chemotherapy regimens, as well as our 
own cohort of patients as described in Aim 1. 
 Several studies have demonstrated that RECIST may be insensitive for 
evaluating response in gastrointestinal stromal tumor (GIST) patients treated with 
imatinib and the Choi criteria have recently emerged as a more sensitive tool for 
assessing the degree of tumor necrosis in response to therapy in that setting.(39, 
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43)  Other soft tissue sarcomas, treated with cytotoxic or biologic therapies, display 
similar patterns of response as GIST treated with imatinib, with patients exhibiting 
long time-to-progression periods despite a lack of significant reduction in their tumor 
size.(44, 45)  Therefore, we chose to use the Choi criteria to assess the activity of 
temozolomide and bevacizumab in HPC/SFT, because we believed that a Choi 
response is more reliable for predicting potential therapeutic benefit than a RECIST 
response is. Using the Choi criteria, one can detect response – or lack of response 
– early in the course of treatment and thereby quickly identify potential non-
responders who may benefit from switching to another therapy. In addition, because 
the Choi criteria for PD are more stringent than RECIST (≥10% increase in tumor 
size), failure of therapy may also be detected earlier. This earlier detection explains 
the shorter median PFS we found when using the Choi criteria than when using 
RECIST. 
 Due to the limitations of the radiologic study archival techniques for our 
historical chemotherapy cohort, we were not able to obtain Choi response rates for 
the majority of the patients.  Although it is theoretically possible that some of the 
patients who had RECIST SD could have achieved Choi PR, the difference in PFS 
(RECIST) – 4.6 months vs 9.3 months -- suggests that chemotherapy may indeed 
be inferior to temozolomide and bevacizumab.  The strength of our assertions are 
limited by the small sample size, which does not allow us to show statistical 
significance between these two groups. 
 Although toxicity data were not systematically gathered for the 
temozolomide-bevacizumab cohort, all available clinic notes and laboratory values 
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were thoroughly reviewed to capture as many side effects as possible. The majority 
of the patients did not exhibit significant complications while receiving treatment as 
scheduled. We did not note any serious side effects (e.g. thromboembolic events, 
cardiac toxicity, or gastrointestinal bleeding) associated with bevacizumab,. 
Although one patient died during treatment, we found no definitive evidence that 
temozolomide and/or bevacizumab directly contributed to the immediate factors that 
resulted in her death.  Rather, the patient’s treating physician believed that her 
overall poor performance status most likely led to her death.  
 Our patients on temozolomide-bevacizumab received a wide range of 
number of doses of therapy. Most patients received treatment until PD or intolerable 
side effects developed, but a few patients were empirically given treatment breaks 
because of patient or physician preferences.  It is difficult to conclude, based on the 
sample size, how long temozolomide-bevacizumab therapy should be continued or 
whether it could be interrupted and resumed without significantly reducing the 
therapeutic benefit.  Also unclear is the potential additional benefit of radiation 
therapy. Three patients with isolated sites of disease had received radiation therapy 
within 4 months before or after temozolomide and bevacizumab. All had achieved 
Choi PR after with their first treatment modality. Two patients were still responding 
when they initiated their second treatment modality, while one was exhibiting tumor 
re-growth. Despite having discontinued their last treatment 18-23 months prior to 
the time of our analysis, all three continue to show a long, durable maintenance of 
their responses, with PFS of 34-43 months to date. Further information regarding 
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the potential synergistic effect of temozolomide-bevacizumab therapy and radiation 
is needed to confirm this encouraging finding. 
 The exact mechanisms by which temozolomide and bevacizumab exert their 
effect on HPC/SFT remain to be determined. Further studies will be needed to 
better elucidate the key therapeutic targets in HPC/SFT. Analysis of our patients’ 
available tumor specimens for potential molecular correlative factors is currently 
under development.  
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Chapter 5 
Potential Pitfalls, Summary and Future Directions 
 
Potential Pitfalls 
 As discussed previously, our study contains all the typical limitations of a 
retrospective review, including the possibilities of patient selection bias and 
observer bias, a relatively small sample size, and the lack of a systematic, 
comprehensive recording of toxicities.  In our retrospective review of our institution’s 
experience of all HPC/SFT patients, despite representing the largest published 
series in the current literature, we are still limited in our abilities to draw firm 
statistically significant conclusions in several clinical variables.  This illustrates the 
fact that HPC/SFT is a frustratingly heterogeneous clinical entity and remains a 
challenge to those who wish to inconclusively define its natural history, prognosis, 
and optimal treatment. 
 Our patient population had a higher proportion of patients who either 
presented with or developed advanced disease, reflecting the referral bias to our 
highly specialized cancer center.  Patients who could not follow up after their initial 
evaluation were also excluded, thus potentially creating another patient selection 
bias.  For the patients treated with temozolomide and bevacizumab, our findings are 
limited by a relatively small sample size.  Although the TMZ-BEV patient cohort 
represent the consecutive series of patients with advanced HPC/SFT encountered  
at MD Anderson, potential patient selection bias certainly exist.   
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 The lack of toxicities attributed to bevacizumab observed in this group may 
be because of the small sample size.  The true toxicity profile of this regimen may in 
fact be greater than described here.  Our phase II trial design, therefore, will 
specifically address this issue by making safety an independent primary endpoint. 
 
Summary and Future Directions 
 To our knowledge, our report nevertheless represents the largest published 
series of patients with advanced HPC/SFT treated with systemic chemotherapy to 
date.  We found that the combination of temozolomide and bevacizumab had a 
remarkably high rate of overall response and a favorable duration of disease 
control.  For these rare sarcoma subtypes that lack a well-established systemic 
therapeutic option, temozolomide-bevacizumab is a promising therapeutic regimen 
that warrants further investigation.   
 The precise mechanisms by which temozolomide and bevacizumab exert 
their effect on HPC/SFT are not clear.  Bevacizumab has been previously combined 
with chemotherapeutic agents to increase vascular permeability, leading to 
subsequent synergistic cytotoxicity. Temozolomide’s activity on soft tissue 
sarcomas as a single agent, although not specifically evaluated in HPC/SFT, has 
not been robust. (27) Bevacizumab may enhance temozlomide’s cytotoxic activity or 
may play an anti-angiogenic role by modulating the VEGF signaling pathway.   
There is evidence, however, that temozolomide may possess intrinsic 
antiangiogenic properties.  Bevacizumab, when combined with temozolomide, may 
also play a synergistic role in its antiangiogenic effect. (46)  The VEGF-VEGFR 
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pathway, which plays a key mediator role in angiogenesis, has recently emerged as 
the key therapeutic target in HPC/SFT. The anti-VEGF receptor tyrosine kinase 
inhibitors sorafenib and sunitinib were recently reported to produce Choi responses 
and disease stabilization for up to 22 months in HPC/SFT patients. (23, 24, 47) 
These examples also provide additional evidence that antiangiogenic approaches to 
targeting HPC/SFT is a rational one.  For future studies, correlative studies 
consisting of deep sequencing analysis, tissue microarrays examining patterns of 
alterations in key antiangiogenic pathways, as well as serum angiogenic and 
cytokine profiles may determine the effects by which this regimen may exert its 
effects on HPC/SFT.   
Our encouraging results should be validated in a prospective trial, which 
would also allow additional insight into the efficacy, safety, and biologic 
mechanisms of temozolomide and bevacizumab in HPC/SFT.  We have therefore 
designed a single-arm phase II study which will prospectively address the true role 
of temozolomide and bevacizumab.  It will also be the first study dedicated solely to 
this rare subtype, which will also allow us to gather information specific to the 
biology of HPC/SFT.  We hope that this study will not only provide a potential new 
therapy for HPC/SFT, but also provide invaluable insight regarding the biological 
drivers of this disease entity and additional potential therapeutic targets. 
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